Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 4/20 | 0.58 |
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | FPR2 | P25090 | 3/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL120625 | 1.00 | MDM2 (0.58) | MDM2MDM4TP53FPR2CASP3 | |
| SCHEMBL29401084 | 1.00 | MDM2 (0.58) | MDM2MDM4TP53FPR2CASP3 | |
| SCHEMBL30309094 | 1.00 | MDM2 (0.58) | MDM2MDM4TP53FPR2CASP3 | |
| SCHEMBL118297 | 1.00 | MDM2 (0.58) | MDM2MDM4TP53FPR2CASP3 | |
| SCHEMBL29401133 | 1.00 | MDM2 (0.58) | MDM2MDM4TP53FPR2CASP3 | |
| SCHEMBL31370557 | 0.97 | MDM2 (0.60) | MDM2MDM4TP53FPR2CASP3 | |
| SCHEMBL118169 | 0.92 | MDM4 (0.59) | MDM2MDM4TP53CASP3KMT2A | |
| SCHEMBL1228254 | 0.92 | MDM4 (0.59) | MDM2MDM4TP53CASP3KMT2A | |
| SCHEMBL119455 | 0.92 | MDM4 (0.59) | MDM2MDM4TP53CASP3KMT2A | |
| SCHEMBL29367434 | 0.92 | MDM4 (0.59) | MDM2MDM4TP53CASP3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| CN-111225679-B | Novel peptide-based cancer imaging agents | 俄亥俄州创新基金会 | 2024-03-29 | — | — | CN | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| US-20230406885-A1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | US | disclosed |
| US-20230338584-A1 | NOVEL PEPTIDE-BASED CANCER IMAGING AGENTS | OHIO STATE INNOVATION FOUNDATION | 2023-10-26 | — | — | US | disclosed |
| US-20230201383-A1 | PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING | RIGSHOSPITALET (DK) | 2023-06-29 | — | — | US | disclosed |
| CN-116194155-A | Urea-based ligands targeting PSMA for prostate cancer radiotherapy and imaging | 哥本哈根大学 | 2023-05-30 | — | — | CN | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| WO-2022234852-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| EP-4043478-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-08-17 | — | — | EP | disclosed |
| CN-114729006-A | Cyclic peptide compounds having Kras inhibitory activity | 中外制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
| EP-3668532-A1 | NOVEL PEPTIDE-BASED CANCER IMAGING AGENTS | Ohio State Innovation Foundation (US) | 2020-06-24 | — | — | EP | disclosed |
| CN-111225679-A | Novel peptide-based cancer imaging agents | 俄亥俄州创新基金会 | 2020-06-02 | — | — | CN | disclosed |
| WO-2019040367-A1 | NOVEL PEPTIDE-BASED CANCER IMAGING AGENTS | OHIO STATE INNOVATION FOUNDATION (US) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406885-A1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | IL1A, IL1B, IL1R1 | MDM2 4355/4885MDM4 4837/4885TP53 3017/4885 |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | MDM2 164/4885MDM4 441/4885TP53 34/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | MDM2 164/4885MDM4 441/4885TP53 34/4885 |
| US-20230201383-A1 | PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING | KLK3, FOLH1, PSMA7 | MDM2 1617/4885MDM4 427/4885TP53 83/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | MDM2 1604/4885MDM4 1294/4885TP53 178/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | MDM2 164/4885MDM4 441/4885TP53 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.